These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37091809)

  • 81. PRAME Is a Potential Carcinogenic Biomarker that Correlates with Patient Prognosis and Tumor Immunity Based on Pan-Cancer Analysis.
    Zhao Q; Zhang Z; Wu Y
    Ann Clin Lab Sci; 2022 Mar; 52(2):185-195. PubMed ID: 35414497
    [TBL] [Abstract][Full Text] [Related]  

  • 82. A comprehensive pan-cancer analysis identifies a novel glycolysis score and its hub genes as prognostic and immunological biomarkers.
    Zheng D; Long S; Xi M
    Transl Cancer Res; 2023 Oct; 12(10):2852-2874. PubMed ID: 37969385
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Prognostic value and immunological role of PD-L1 gene in pan-cancer.
    Wang Y; Jiang H; Fu L; Guan L; Yang J; Ren J; Liu F; Li X; Ma X; Li Y; Cai H
    BMC Cancer; 2024 Jan; 24(1):20. PubMed ID: 38166842
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A Systematic Immune and Prognostic Analysis of CD48 Interaction with Tumor Microenvironment in Pan-Cancer.
    He M; Yu J; Chen S; Mi H
    Int J Gen Med; 2023; 16():5255-5269. PubMed ID: 38021043
    [TBL] [Abstract][Full Text] [Related]  

  • 85. ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis.
    Lin Y; Zhang Y; Tuo Z; Gao L; Ding D; Bi L; Yu D; Lv Z; Wang J; Chen X
    BMC Cancer; 2023 Mar; 23(1):285. PubMed ID: 36978046
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A pan-cancer characterization of immune-related NFIL3 identifies potential predictive biomarker.
    Fei Q; Zhang X; Wang S; Shu G; Yin G
    J Cancer; 2024; 15(5):1271-1286. PubMed ID: 38356719
    [No Abstract]   [Full Text] [Related]  

  • 87. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
    Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
    Front Immunol; 2022; 13():849592. PubMed ID: 35444654
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
    Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
    Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Pan-Cancer analysis shows that ACO2 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including hepatocellular carcinoma.
    Wang Z; Zheng W; Chen Z; Wu S; Chang H; Cai M; Cai H
    Front Oncol; 2022; 12():1055376. PubMed ID: 36531056
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Comprehensive analysis of POLH-AS1 as a prognostic biomarker in hepatocellular carcinoma.
    Dong Y; Chen X; Yang S; Fu Y; Wang L; Gao X; Chen D; Xu L
    BMC Cancer; 2024 Sep; 24(1):1112. PubMed ID: 39242532
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Roles of HMGBs in Prognosis and Immunotherapy: A Pan-Cancer Analysis.
    Lin T; Zhang Y; Lin Z; Peng L
    Front Genet; 2021; 12():764245. PubMed ID: 34777483
    [No Abstract]   [Full Text] [Related]  

  • 92. Comprehensive Analysis of NPSR1-AS1 as a Novel Diagnostic and Prognostic Biomarker Involved in Immune Infiltrates in Lung Adenocarcinoma.
    Zhang H; Yuan J; Xiang Y; Liu Y
    J Oncol; 2022; 2022():2099327. PubMed ID: 36284635
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Long non-coding RNA SLC16A1-AS1: its multiple tumorigenesis features and regulatory role in cell cycle in oral squamous cell carcinoma.
    Feng H; Zhang X; Lai W; Wang J
    Cell Cycle; 2020 Jul; 19(13):1641-1653. PubMed ID: 32450050
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Comprehensive pan-cancer analysis of ZNF337 as a potential diagnostic, immunological, and prognostic biomarker.
    Zhang D; Liang P; Xia B; Wu J; Hu X
    BMC Cancer; 2024 Aug; 24(1):987. PubMed ID: 39123194
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Systematic pan-cancer analysis identifies cuproptosis-related gene DLAT as an immunological and prognostic biomarker.
    Xu L; Wu P; Rong A; Li K; Xiao X; Zhang Y; Wu H
    Aging (Albany NY); 2023 May; 15(10):4269-4287. PubMed ID: 37199628
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Comprehensive pan-cancer analysis unveils the significant prognostic value and potential role in immune microenvironment modulation of TRIB3.
    Hu C; Li Q; Xiang L; Luo Y; Li S; An J; Yu X; Zhang G; Chen Y; Wang Y; Wang D
    Comput Struct Biotechnol J; 2024 Dec; 23():234-250. PubMed ID: 38161736
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Integrated pan-cancer analysis of CSMD2 as a potential prognostic, diagnostic, and immune biomarker.
    Zhang H; Huang T; Ren X; Fang X; Chen X; Wei H; Sun W; Wang Y
    Front Genet; 2022; 13():918486. PubMed ID: 36061177
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
    Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
    J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Pan-Cancer Analysis Revealed
    Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
    J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
    [TBL] [Abstract][Full Text] [Related]  

  • 100. CYP1B1-AS1 Is a Novel Biomarker in Glioblastoma by Comprehensive Analysis.
    Ye T; Li LL; Peng XM; Li Q
    Dis Markers; 2021; 2021():8565943. PubMed ID: 35003394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.